Drug Trial Radar · NCT06580314
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
880
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
Dec 31, 2034
Study completion Dec 31, 2034
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Conditions
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube High Grade Serous Adenocarcinoma
- Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor
- FIGO Stage III Ovarian Cancer 2014
- FIGO Stage IV Ovarian Cancer 2014
- Ovarian Carcinoma
- Ovarian Carcinosarcoma
- Ovarian High Grade Endometrioid Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Primary Peritoneal Carcinosarcoma
- Primary Peritoneal Endometrioid Adenocarcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
BevacizumabBiological
Given IV
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
OlaparibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) at least 360 days after randomization (PFS360)Time frame: From completing 360 days of maintenance therapy to disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) or death, whichever occurs first, assessed up to 5 years
Locations
709 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Recruiting
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Recruiting
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Recruiting
Alaska Women's Cancer Care
Anchorage, Alaska · Recruiting
Katmai Oncology Group
Anchorage, Alaska · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
Fairbanks Memorial Hospital
Fairbanks, Alaska · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
CARTI Cancer Center
Little Rock, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Kaiser Permanente-Deer Valley Medical Center
Antioch, California · Recruiting
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Active not recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Recruiting
Mills-Peninsula Medical Center
Burlingame, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Eden Hospital Medical Center
Castro Valley, California · Recruiting
Sutter Davis Hospital
Davis, California · Recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Stanford Cancer Center Emeryville
Emeryville, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Palo Alto Medical Foundation-Fremont
Fremont, California · Recruiting
Fresno Cancer Center
Fresno, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Kaiser Permanente-Fresno
Fresno, California · Recruiting
Kaiser Permanente South Bay
Harbor City, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
Showing 40 of 709 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.